钠-葡萄糖共转运蛋白2抑制剂对心脏离子通道作用的研究进展  

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Ion Channels

作　　者：王森 钱进 姜苏蓉 WANG Sen;QIAN Jin;JIANG Surong(Department of Geriatric Cardiology,Jiangsu Province Hospital,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,Jiangsu,China)

机构地区：[1]南京医科大学第一附属医院江苏省人民医院老年心血管科,江苏南京210029

出　　处：《心血管病学进展》2024年第11期1013-1015,1020,共4页Advances in Cardiovascular Diseases

基　　金：江苏省干部保健课题(BJ21019)。

摘　　要：钠-葡萄糖共转运蛋白2(SGLT2)抑制剂是一种新型抗心力衰竭药物。随着SGLT2抑制剂的应用,其对心律失常的潜在作用也逐渐受到关注。心脏钠、钾、钙等离子通道有顺序地开放并保持动态平衡,保证了心脏电信号的正常传导。如果以上离子通道之间平衡失调,就可引起心脏电信号传导紊乱,诱发心律失常。近年研究发现SGLT2抑制剂可改善心脏离子通道的异常,此作用亦为SGLT2抑制剂抗心律失常的机制之一。现从离子通道的角度对该类药物抗心律失常作用的电生理基础进行综述。Sodium-glucose cotransporter 2(SGLT2)inhibitor is a new type of anti-heart failure drug.With the application of SGLT2 inhibitors,their potential effects on arrhythmias have gradually received attention.The sequential opening and dynamic balance of cardiac ion channels,such as sodium,potassium and calcium channels,are necessary to ensure the normal transmission of cardiac electrical signals.If the balance of ion channels is changed,it can cause heart electrical signals disorder and induce arrhythmia.In recent years,some studies have found that SGLT2 inhibitors improve cardiac ion channel abnormalities,which is one of the anti-arrhythmic mechanisms of SGLT2 inhibitors.This article reviews the electrophysiological basis of antiarrhythmic effects of this type of drugs from the perspective of ion channels.

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 心律失常 离子通道 

分 类 号：R54[医药卫生—心血管疾病]